Filing Date Form TypeDescription   
   
Data pager
 Page 1 of 18, items 1 to 13 of 227.
2021-03-298-KCurrent report, items 1.01, 8.01, and 9.01 Acc-no: 0001213900-21-018348 (34 Act)  Size: 2 MB
2021-03-238-KCurrent report, item 8.01 Acc-no: 0001213900-21-017305 (34 Act)  Size: 18 KB
2021-03-22S-8Securities to be offered to employees in employee benefit plansAcc-no: 0001213900-21-016974 (33 Act)  Size: 495 KB
2021-03-228-KCurrent report, items 8.01 and 9.01 Acc-no: 0001213900-21-016933 (34 Act)  Size: 31 KB
2021-03-168-KCurrent report, item 8.01 Acc-no: 0001213900-21-015756 (34 Act)  Size: 18 KB
2021-03-12S-3Registration statement under Securities Act of 1933Acc-no: 0001213900-21-015129 (33 Act)  Size: 221 KB
2021-03-11424B5Prospectus [Rule 424(b)(5)]Acc-no: 0001213900-21-014720 (33 Act)  Size: 213 KB
2021-03-118-KCurrent report, items 1.01 and 9.01 Acc-no: 0001213900-21-014649 (34 Act)  Size: 331 KB
2021-03-098-KCurrent report, items 8.01 and 9.01 Acc-no: 0001213900-21-014276 (34 Act)  Size: 29 KB
2021-03-058-KCurrent report, items 2.02 and 9.01 Acc-no: 0001213900-21-013731 (34 Act)  Size: 29 KB
2021-03-0410-KAnnual report [Section 13 and 15(d), not S-K Item 405]Acc-no: 0001213900-21-013456 (34 Act)  Size: 5 MB
2021-03-028-KCurrent report, items 8.01 and 9.01 Acc-no: 0001213900-21-012742 (34 Act)  Size: 29 KB
2021-01-258-KCurrent report, item 5.02 Acc-no: 0001213900-21-004031 (34 Act)  Size: 30 KB


INmune Bio, Inc. Announces Professor Mark Lowdell, PhD, CSO to Deliver Presentations at Two Upcoming Medical Meetings
03/22/2021 1:00 PM

Innate Killer Digital Summit 2021, which is being held March 23-25 Festival of Biologics USA: World Immunotherapy Congress 2021, which is being held March 29-April 1 LA JOLLA, Calif, March 22, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that Professor Mark Lowdell, PhD, Chief Scientific Officer of INmune Bio, will deliver presentations at two upcoming medical meetings. Event details: Innate Killer Digital Summit 2021, March 23-25Title: Exploring the Network of Cellular Interactions of NK Cells in the Tumor MicroenvironmentDate: Thursday, March 25Time: 3:30 EDT In this presentation, Dr. Lowdell will discuss the company’s latest data and the discovery of a new mechanism of action of its NK-priming immunotherapy, “INKmune”. INKmune™ is a clinical stage proprietary tumor cell line which is administered intravenously and primes NK cells to kill otherwise resistant tumors. INKmune™-primed NK cells have been shown to kill a wide variety of solid and hematological cancer cells in preclinical studies. Use of two of the latest state-of-the-art cell:cell analysis technologies has demonstrated that INKmune™ increases NK cell killing of tumor cells by strengthening the binding of the NK to the tumor cell; the avidity. Our preclinical studies show that the robust immune synapse created by INKmune™ priming is greater than that induced by conventional cytokine activation (IL-2 or IL-15) and allows more rapid NK-mediated killing which was confirmed by videomicrography. These INKmune™-primed NK cells are not only more efficient killers of tumor cells but are able to overcome inhibition by regulatory cells and hypoxia in the tumor microenvironment. Additional information about the summit, including registration details, can be found at: https://innate-killer.com/ Festival of Biologics USA: World Immunotherapy Congress 2021, March 29-April 1Session: Cell and Gene TherapyTitle: Enhancing the Cellular Interactions Between NK Cells and Tumor CellsDate: Monday, March 29Time: 11:00am EDT This second presentation will focus on the immunobiology of the NK:tumor immune synapse and the impact of tumor cell susceptibility to NK killing on NK exhaustion and the ability to lyse multiple target cells. Additional information can be found at: https://www.terrapinn.com/conference/festival-of-biologics-usa/index.stm About INKmune™ INKmune™ is an experimental biologic undergoing clinical trials that is a pharmaceutical-grade, replication incompetent tumor cell that delivers essential priming signals to patients’ resting NK cells. INKmune™ is delivered by IV infusion. Once in the patient’s system, INKmune™ comes in contact with resting NK cells. The interaction converts NK cells to “primed NK cell” (pNK) similar to an “on-off” switch. pNK then remain primed until they contact and kill cancer cells. INKmune-primed NK cells have a mRNA fingerprint which is fundamentally different to NK cells activated with IL-2 or IL-15. About INmune Bio, Inc. INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s and Treatment Resistant Depression (XPro1595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com. Information about Forward-Looking Statements Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, Quellor™, XPro1595, LIVNate™, and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. INmune Bio Contact: David Moss, CFO (858) 964-3720 DMoss@INmuneBio.com Investor Contact: Chuck Padala LifeSci Advisors (646) 627-8390 chuck@lifesciadvisors.com Media Contact: Meredith Sosulski, Ph.D. LifeSci Communications (929) 469-3851 msosulski@lifescicomms.com

INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021
03/08/2021 2:00 PM

LA JOLLA, Calif, March 08, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that its management team is scheduled to participate in two upcoming virtual investor conferences in March 2021. 33rd Annual Roth Virtual ConferencePanel Discussion: Therapeutics Against SARS-CoV-2 – Viral Variants Will Not Fade AwayPanel Date: Monday, March 15, 2021 Panel Time: 12:00 PM Eastern TimeInterested parties may register for the panel here Oppenheimer 31st Annual Healthcare ConferencePresentation Date: Tuesday, March 16, 2021Presentation Time: 1:10 PM Eastern TimeInterested parties may register for the panel here Please contact your representative at either Roth or Oppenheimer to schedule a virtual one-on-one meeting with INmune Bio during the respective conference. About INmune Bio, Inc.INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s (XPro595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com. Information about Forward-Looking StatementsClinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, Quellor™, XPro1595, LIVNate™, and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. INmune Bio Contact:David Moss, CFO (858) 964-3720 DMoss@INmuneBio.com Investor Contact:Chuck Padala LifeSci Advisors, LLC(917) 741-7792Chuck@lifesciadvisors.com

INmune Bio, Inc. (INMB) Q4 2020 Earnings Call Transcript
03/06/2021 12:30 AM

Image source: The Motley Fool. INmune Bio, Inc. (NASDAQ: INMB)Q4 2020 Earnings CallMar 04, 2021, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGreetings, and welcome to the INmune Bio fourth-quarter 2020 earnings conference call.

INmune Bio, Inc. Announces Fourth Quarter and Full Year 2020 Results and Provides Business Update
03/04/2021 9:15 PM

Company to host conference call today, March 4, at 4:30pm ETLA JOLLA, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today reported its financial results for the year ended December 31, 2020 and provided a business update. “A key highlight since our last quarterly update is the updated interim data announced from our ongoing Phase 1b study evaluating XPro1595 in Alzheimer’s disease in January,” stated RJ Tesi, M.D., chief executive officer of INmune Bio. “These data demonstrate that XPro1595 decreases neuroinflammation using multiple biomarkers of inflammation in patients with Alzheimer’s disease. We also gained insight into the consequences of decreasing neuroinflammation in these patients for extended period of time which includes decrease in biomarkers on neurodegeneration and improvement of biomarkers of synaptic function. We remain committed to initiating a Phase 2 study later this year. “Our Phase 2 trial of Quellor for the treatment of for pulmonary complications patients with COVID-19 continues to enroll patients. While the emergence of safe and effective vaccines appears to be having an impact on infection and hospitalization rates, effective treatment of serious complications remains a significant unmet need. Both the TRD program with XPro1595 and the INKmune program to treat patients with high-risk MDS will begin to enroll patients once the pandemic is better controlled in the US and UK, respectively. We look forward to data from these important studies. “Finally, we strengthened our balance sheet by raising an additional $28.4 million of net proceeds from the sale of 1,439,480 shares of common stock at an average price of $20.17 through our ATM during January and February 2021, which provides additional capital to fund the Company into 2022.” Recent Corporate Highlights DN-TNF Platform Highlights: Announced interim Phase 1b data demonstrating that XPro1595 decreased biomarkers of neuroinflammation and neurodegeneration, as measured by multiple analytic platforms in patients with Alzheimer’s disease. Data supports initiation of a blinded, randomized, placebo-controlled Phase 2 study in 2021 to explore the clinical impact of XPro1595 in patients with Alzheimer’s disease.The biomarker data was presented during a Key Opinion Leader webinar on January 21, 2021, a replay of which can be accessed here. Announced that the first patient has been dosed in the company’s Phase 2 trial of Quellor™ for pulmonary complications in COVID-19 patients. Financial Highlights: Subsequent to the end of the fourth quarter, raised a net of approximately $28.4 million from the sale of 1,439,480 shares of common stock through a pre-existing open sale market agreement (At-the-Market, or ATM) at an average price of $20.17 per share. Upcoming Milestones: Report on the first 100 patients enrolled in the company’s Quellor trial in COVID-19 which will provide proof-of-concept and inform a “go/no go” decision by the Data Safety Monitoring Board (DSMB).Additional data from the Phase 1b Alzheimer's disease program.Initiate XPro1595 Phase 2 program for Alzheimer's disease in patients with neuro-inflammation.Initiate XPro1595 Phase 2 program for treatment resistant depression.Initiate Phase 1 program with INKmune™ for high-risk MDS. The company plans additional clinical trials after the COVID-19 pandemic has been controlled. The exact timing of these trials cannot be predicted at this time. LIVNate Phase 2 program for NASH.INB03 Phase 2 program for MUC4 expressing cancer. Financial Results for the Year Ended December 31, 2020: Net loss attributable to common stockholders for the year ended December 31, 2020 was approximately $12.1 million, compared to approximately $7.7 million for the year ended December 31, 2019. Research and development expense totaled approximately $5.9 million for the year ended December 31, 2020, compared to approximately $3.3 million during the year ended December 31, 2019. General and administrative expense was approximately $6.3 million for the year ended December 31, 2020, compared to approximately $6.0 million during the year ended December 31, 2019. As of December 31, 2020, the Company had cash and cash equivalents of approximately $22.0 million and no debt. Subsequent to December 31, 2020, the company raised a net of approximately $28.4 million at an average price of $20.17 per share from its pre-existing ATM facility. As of March 4, 2021, the Company had approximately 14.9 million common shares outstanding. Earnings Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Date: Thursday, March 4, 2021Time: 4:30 PM Eastern TimeParticipant Dial-in: 877-407-0784Participant Dial-in (international): 201-689-8560 Live Webcast Link: http://public.viavid.com/index.php?id=143196 A transcript will follow approximately 24 hours from the scheduled call. A replay will also be available through March 11 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering PIN no. 13715561. About XPro1595 XPro1595 is a next-generation inhibitor of tumor necrosis factor (TNF) that is currently in clinical trial and acts differently than currently existing TNF inhibitors in that it neutralizes soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro1595 could have substantial beneficial effects in patients with neurologic disease by decreasing neuroinflammation. For more information about the importance of targeting neuroinflammation in the brain to improve cognitive function and restore neuronal communication visit this section of the INmune Bio’s website. About INmune Bio, Inc. INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is in clinical trial to determine if it can treat for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s and treatment resistant depression (XPro595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com. Forward Looking Statements Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595, LIVNate, Quellor™ and INKmune are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. Our two platforms are beginning clinical trials and there cannot be any assurance of the success of these trials. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. INmune Bio Contact: David Moss, CFO (858) 964-3720DMoss@INmuneBio.com Investor Contact:Chuck PadalaLifeSci Advisors(646) 627-8390chuck@lifesciadvisors.com Media Contact:Meredith Sosulski, Ph.D.LifeSci Communications(929) 469-3851msosulski@lifescicomms.com The following table summarizes our results of operations for the periods indicated: INMUNE BIO, INC. CONSOLIDATED BALANCE SHEETS(Unaudited) December 31,2020 December 31,2019 ASSETS CURRENT ASSETS Cash $21,966,883 $6,995,525 Research and development tax credit receivable 1,686,065 568,139 Other tax receivable 112,684 77,225 Prepaid expenses 220,090 97,623 Prepaid expenses – related party - 26,266 TOTAL CURRENT ASSETS 23,985,722 7,764,778 Operating lease – right of use asset – related party 156,214 191,543 Acquired in-process research and development intangible assets 16,514,000 16,514,000 TOTAL ASSETS $40,655,936 $24,470,321 LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable and accrued liabilities $1,518,113 $401,989 Accounts payable and accrued liabilities – related parties 33,664 290,102 Deferred liabilities 190,612 - Operating lease, current liability – related party 33,873 8,288 TOTAL CURRENT LIABILITIES 1,776,262 700,379 Long-term operating lease liability – related party 126,286 160,164 TOTAL LIABILITIES 1,902,548 860,543 COMMITMENTS AND CONTINGENCIES STOCKHOLDERS’ EQUITY Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding - - Common stock, $0.001 par value, 200,000,000 shares authorized, 13,481,283 and 10,770,948 shares issued and outstanding, respectively 13,481 10,771 Additional paid-in capital 72,104,539 44,833,703 Common stock issuable - 50,000 Accumulated other comprehensive income (loss) 10,708 (8,515)Accumulated deficit (33,375,340) (21,276,181)TOTAL STOCKHOLDERS’ EQUITY 38,753,388 23,609,778 TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $40,655,936 $24,470,321 INMUNE BIO, INC. CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited) 2020 2019 REVENUE $10,916 $- OPERATING EXPENSES General and administrative 6,321,097 6,016,056 Research and development 5,917,495 3,281,945 Gain on waiver of common stock issuable - (1,542,000)Total operating expenses 12,238,592 7,756,001 LOSS FROM OPERATIONS (12,227,676) (7,756,001) OTHER INCOME Other income 128,517 77,688 Total other income 128,517 77,688 NET LOSS $(12,099,159) $(7,678,313) Net loss per common share – basic and diluted $(1.01) $(0.75) Weighted average number of common shares outstanding – basic and diluted 11,988,492 10,272,641 COMPREHENSIVE LOSS Net loss $(12,099,159) $(7,678,313)Other comprehensive (income) loss – foreign currency translation 19,223 (15,044)Total comprehensive loss $(12,079,936) $(7,693,357) INMUNE BIO, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited) 2020 2019 CASH FLOWS FROM OPERATING ACTIVITIES: Net loss $(12,099,159) $(7,678,313)Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation 3,112,004 4,096,538 Gain on waiver of common stock issuable - (1,542,000)Changes in operating assets and liabilities: Research and development tax credit receivable (1,117,926) 24,076 Other tax receivable (35,459) (39,843)Joint development cost receivable - 17,989 Prepaid expenses (122,467) (82,071)Prepaid expenses – related party 26,266 (26,266)Accounts payable and accrued liabilities 1,116,124 (151,232)Accounts payable and accrued liabilities – related parties (40,677) 19,557 Deferred liabilities 190,612 - Operating lease liability – related party 27,036 (23,091)Net cash used in operating activities (8,943,646) (5,384,656) CASH FLOWS FROM FINANCING ACTIVITIES: Net proceeds from sale of common stock 24,907,781 12,209,021 Purchase of common stock (1,012,000) - Net cash provided by financing activities 23,895,781 12,209,021 Impact on cash from foreign currency translation 19,223 (15,044) NET INCREASE IN CASH 14,971,358 6,809,321 CASH AT BEGINNING OF YEAR 6,995,525 186,204 CASH AT END OF YEAR $21,966,883 $6,995,525 SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION: Cash paid for income taxes $- $- Cash paid for interest expense $- $- NONCASH INVESTING AND FINANCING ACTIVITIES: Capital contribution $215,761 $- Cashless exercise of warrants $2 $- Issuance of common stock issuable $50,000 $3,084,000 Issuance of warrants to placement agents $- $247,452

INmune Bio, Inc. to Host Earnings Call
03/04/2021 7:30 PM

NEW YORK, NY / ACCESSWIRE / March 4, 2021 / INmune Bio, Inc. (NASDAQ:INMB) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 4, 2021 at 4:30 PM Eastern Time.

INmune Bio, Inc. to Report Fourth Quarter and Full Year 2020 Financial Results and Provide a Corporate Update on Thursday, March 4
02/25/2021 2:00 PM

Management to host conference call and webcast at 4:30 pm ET on that day LA JOLLA, Calif, Feb. 25, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it will host a conference call on Thursday, March 4, 2021 at 4:30 PM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2020 and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Fourth Quarter Conference Call when reaching an operator. Date: March 4, 2021 Time: 4:30 PM Eastern Time Participant Dial-in: 1-877-407-0784Participant Dial-in (international): 1-201-689-8560Live Webcast Link: http://public.viavid.com/index.php?id=143196 A transcript will follow approximately 24 hours from the scheduled call. A replay will also be available through March 11, 2021 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering PIN no. 13715561. About INmune Bio, Inc. INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s (XPro595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com. Information about Forward-Looking Statements Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, Quellor™, XPro1595, LIVNate™, and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. INmune Bio Contact:David Moss, CFO (858) 964-3720 DMoss@INmuneBio.com Investor Contact:Chuck Padala LifeSci Advisors, LLC(917) 741-7792Chuck@lifesciadvisors.com

We Think INmune Bio (NASDAQ:INMB) Can Easily Afford To Drive Business Growth
01/25/2021 6:50 AM

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, INmune Bio...

Why INmune Bio Stock Soared Then Sank Today
01/21/2021 8:53 PM

INmune's shares were sinking 17% as of 3:39 p.m. EST. The big jump came after the biotech announced encouraging results from a phase 1b study evaluating XPro1595 in treating Alzheimer's disease. It's not all that surprising to see such high volatility for a clinical-stage biotech stock.

The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping
01/21/2021 1:05 PM

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 20) * 10X Genomics Inc (NASDAQ: TXG) * ABIOMED, Inc. (NASDAQ: ABMD) * Aclaris Therapeutics Inc (NASDAQ: ACRS) * Adamis Pharmaceuticals Corp(NASDAQ: ADMP) (announced IND submission of Tempol for COVID-19 treatment) * Akari Therapeutics PLC (NASDAQ: AKTX) * Aligos Therapeutics Inc (NASDAQ: ALGS) * Alimera Sciences Inc (NASDAQ: ALIM) * Atea Pharmaceuticals Inc (NASDAQ: AVIR) * Beigene Ltd (NASDAQ: BGNE) * Bicycle Therapeutics PLC (NASDAQ: BCYC) * BIO-TECHNE Corp (NASDAQ: TECH) * BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) * Biodesix Inc (NASDAQ: BDSX) * BioVie Inc (NASDAQ: BIVI) * Caladrius Biosciences Inc (NASDAQ: CLBS) * Cara Therapeutics Inc (NASDAQ: CARA) * CareDx Inc (NASDAQ: CDNA) * Castle Biosciences Inc (NASDAQ: CSTL) * Celcuity Inc (NASDAQ: CELC) * Cellectis SA (NASDAQ: CLLS) * Celsius Holdings, Inc. (NASDAQ: CELH) * Dare Bioscience Inc (NASDAQ: DARE) * DermTech Inc (NASDAQ: DMTK) * Dyne Therapeutics Inc (NASDAQ: DYN) * Edap Tms SA (NASDAQ: EDAP) (reacted to fourth-quarter results) * Eli Lilly And Co (NYSE: LLY) * ENDRA Life Sciences Inc (NASDAQ: NDRA) * ESSA Pharma Inc (NASDAQ: EPIX) * Evelo Biosciences Inc (NASDAQ: EVLO) (announced positive Phase 1b data for drug to treat atopic dermatitis) * EXACT Sciences Corporation (NASDAQ: EXAS) * Fulgent Genetics Inc (NASDAQ: FLGT) * Genetron Holdings Ltd - ADR (NASDAQ: GTH) * Gritstone Oncology Inc (NASDAQ: GRTS) (announced a nonexclusive license to Genevant's LNP technology to develop vaccines against SARS-CoV-2) * Guardant Health Inc (NASDAQ: GH) * Halozyme Therapeutics, Inc. (NASDAQ: HALO) * Idera Pharmaceuticals Inc (NASDAQ: IDRA) * Ideaya Biosciences Inc (NASDAQ: IDYA) * ImmuCell Corporation (NASDAQ: ICCC) * Inari Medical Inc (NASDAQ: NARI) * Infinity Pharmaceuticals Inc. (NASDAQ: INFI) * Inspire Medical Systems Inc (NYSE: INSP) * Insulet Corporation (NASDAQ: PODD) * Integra Lifesciences Holdings Corp (NASDAQ: IART) * Inventiva ADR Representing Ord Shs (NASDAQ: IVA) * iTeos Therapeutics Inc (NASDAQ: ITOS) * Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) * Johnson & Johnson (NYSE: JNJ) * Jounce Therapeutics Inc (NASDAQ: JNCE) * Krystal Biotech Inc (NASDAQ: KRYS) * LeMaitre Vascular Inc (NASDAQ: LMAT) * Ligand Pharmaceuticals Inc. (NASDAQ: LGND) * Maravai Lifesciences Holdings Inc (NASDAQ: MRVI) * Merus NV (NASDAQ: MRUS) * Mustang Bio Inc (NASDAQ: MBIO) * Natera Inc (NASDAQ: NTRA) * Neuronetics Inc (NASDAQ: STIM) * Obalon Therapeutics Inc (NASDAQ: OBLN) (announced a deal to merge with ReShape Lifesciences) * Organogenesis Holdings Inc (NASDAQ: ORGO) * Orphazyme A S ADR (NASDAQ: ORPH) * Pacific Biosciences of California Inc (NASDAQ: PACB) * PRA Health Sciences Inc (NASDAQ: PRAH) * Precision BioSciences Inc (NASDAQ: DTIL) * Relay Therapeutics Inc (NASDAQ: RLAY) * Repligen Corporation (NASDAQ: RGEN) * Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) * Profound Medical Corp (NASDAQ: PROF) * Stoke Therapeutics Inc (NASDAQ: STOK) * Supernus Pharmaceuticals Inc (NASDAQ: SUPN) * Surface Oncology Inc (NASDAQ: SURF) * Syneos Health Inc (NASDAQ: SYNH) * Titan Medical Inc. (NASDAQ: TMDI) * Twist Bioscience Corp (NASDAQ: TWST) * Vericel Corp (NASDAQ: VCEL) * Xencor Inc (NASDAQ: XNCR) * Zai Lab Ltd - ADR (NASDAQ: ZLAB)Down In The Dumps None of the biotech/medical device/diagnostic stocks hit 52-week highs in the session.Stocks In Focus Bristol-Myers Squibb's Regulatory Application For Esbriet Label Expansion Accepted For Priority Review Bristol-Myers Squibb Co (NYSE: BMY) said the FDA has accepted its supplemental New Drug Application and granted priority review for Esbriet for the treatment of unclassifiable interstitial lung disease. The FDA is expected to make a decision on approval by May 2021.Addex Says Licensee J&J's Janssen Unit Approved To Start Phase 2a Epilepsy Drug Study Addex Therapeutics ADR (NASDAQ: ADXN) said its partner Johnson & Johnson's Janssen Pharmaceuticals has received FDA investigational new drug approval to begin a Phase 2a proof-of-concept study with the selective metabotropic glutamate type 2 receptor positive allosteric modulator JNJ-40411813 in patients with epilepsy. The first patient is expected to be treated during the second quarter of 2021.Janssen licensed the pipeline asset from Addex.Addex shares were soaring 67.87% to $17.10 premarket Thursday.Boston Scientific To Buy Cardiac Health Solutions Provider Preventice Boston Scientific Corporation (NASDAQ: BSX) said it has entered into a definitive agreement to acquire Preventice Solutions, Inc., a privately held company offering a full portfolio of mobile cardiac health solutions and services, ranging from ambulatory cardiac monitors -- including short and long-term Holter monitors -- to cardiac event monitors and mobile cardiac telemetry.The transaction consists of an upfront cash payment of $925 million and up to an additional $300 million in potential commercial milestone payments.Boston now holds an equity stake of approximately 22%, which is expected to result in a net payment of approximately $720 million upon closing and a milestone payment of up to approximately $230 million.INmune Bio Reports Positive Early Stage Data For Alzheimer's Drug INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company, said results from a Phase 1b study demonstrate that its Alzheimer's disease candidate XPro1595 led to decreasing neuroinflammation, with significant improvements in biomarkers of neurodegeneration and synaptic function.The stock was rallying 41.88% to $35.64 premarket Thursday.Related Link: The Week Ahead In Biotech: FDA To Issue Decisions On Merck And Aurinia Drug Applications Lineage Cell CFO to Depart Lineage Cell Therapeutics Inc (NYSE: LCTX) said Brandi Roberts, its chief financial officer, provided notice of her resignation Jan. 15 in order to accept a leadership position at another company. Brian Culley, Lineage's CEO, will serve as interim chief financial officer until a CFO has been appointed, the company said.The stock was up 9.67% at $3.29 premarket. Dynavax Appoints Ironwood Pharma Executive As CFO Dynavax Technologies Corporation(NASDAQ: DVAX) announced the appointment of Kelly MacDonald as SVP and chief financial officer effective March 1. MacDonald will replace Michael Ostrach, who is retiring following a 14-year stint at the company.MacDonald last served as chief accounting officer and VP of finance at Ironwood Pharmaceuticals, Inc.(NASDAQ: IRWD).Ora Sure's Saliva Collection Device Included In FDA Authorized Exome Sequencig-Based Platform OraSure Technologies, Inc. (NASDAQ: OSUR) said its Oragene Dx (OGD-610) saliva collection device was included as a component in the De Novo authorization granted by the FDA to Helix for their Helix Laboratory Platform, a whole exome sequencing platform. This is the first exome sequencing-based platform authorized by the FDA. Oragene Dx is a product of OraSure's DNA Genotek subsidiary.The stock was up 8.18% to $14.42 in premarket trading Thursday.Offerings Inovio Pharmaceuticals Inc (NASDAQ: INO), which is developing a DNA vaccine for the coronavirus vaccine, priced its underwritten public offering of 17.7 million shares of its common stock at $8.5 per share, for raising gross proceeds of $150.5 million. All of the shares are being sold by Inovio. The company said it intends to use the net proceeds from this offering for the development of its clinical pipeline, including clinical development expenses relating to INO-4800 and R&D expenses, and for general corporate purposes, including working capital and general and administrative expenses.The stock shed 7.3% premarket to $9.01.Dyne Therapeutics priced its underwritten public offering of 6 million shares of its common stock at a public offering price of $28 per share, for raising gross proceeds of $168 million. All of the shares are being offered by Dyne.OncoSec Medical Inc (NASDAQ: ONCS) said it intends to offer shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by the company.The stock was down 4.51% premarket at $5.50. OncoCyte Corp (NYSE: OCX) announced that it has entered into definitive agreements with its two largest institutional investors -- Pura Vida and Broadwood Partners -- to purchase approximately $25 million of its common shares in a registered offering priced at $3.424 per share.The stock jumped 10.68% premarket to $4.56.InVitae Corp (NYSE: NVTA) said it has commenced an underwritten public offering of $400 million of shares of its common stock. All of the shares are being offered by the company.The stock was down 2.86% premarket at $55.30. Related Link: Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates See more from Benzinga * Click here for options trades from Benzinga * The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study * The Week Ahead In Biotech: FDA To Issue Decisions On Merck And Aurinia Drug Applications(C) 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

INmune Bio, Inc. Announces XPro1595 Found to Decrease Neuroinflammation and Neurodegeneration Biomarkers in Patients with Alzheimer’s Disease in Phase 1b Trial
01/21/2021 12:00 PM

Interim data show CSF biomarkers of neurodegeneration and synaptic dysfunction as well as neuroimaging biomarkers improved after three months of therapy with XPro1595 Data support initiation of blinded randomized Phase 2 study before year end Company to host Key Opinion Leader Webinar Today, January 21, at 8:00am ET LA JOLLA, Calif, Jan. 21, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that results from a Phase 1b study demonstrate that XPro1595, an investigational dominant-negative protein that neutralizes soluble TNF, decreases biomarkers of neuroinflammation across multiple measures and assays, including cerebrospinal fluid (CSF) and MRI, in patients with Alzheimer’s disease (AD). The data suggest that decreasing neuroinflammation results in significant improvements in biomarkers of neurodegeneration and synaptic function. The goal of the ongoing Phase 1b open label dose escalation trial is to demonstrate that XPro1595, when given as a subcutaneous injection once weekly, will decrease neuroinflammation in patients with mild to moderate AD. The data shows that cytokine/chemokine CSF levels after 12 weeks of therapy were decreased, with multiple statistically significant reductions (e.g., c-reactive protein (CRP) & YKL-40, p<0.0001). Additionally, there was a significant correlation between neuroinflammation, as measured by CSF, and MRI white matter free water (R2=0.75; p<0.01), a validated biomarker of neuroinflammation. This supports the use of white matter free water as a neuroinflammatory biomarker of treatment response in future studies. Proteomic CSF analysis revealed that targeting neuroinflammation led to a significant change in multiple AD-related pathways including immune/inflammatory response, CNS neuronal function and injury, dendritic spine morphogenesis and synaptic plasticity. Notably, the analysis found an approximate two-fold reduction in the neurodegeneration markers visinin-like protein 1 (VILIP-1) and neurofilament light (NFL), and an approximate three-fold change in contactin-2 and a half-fold change in neurogranin, both proteins associated with synaptic plasticity (p<0.0001). “Demonstrating changes in neuroinflammatory biomarkers across multiple measures (CSF and MRI) and assays in a small dataset gives us great confidence that XPro1595 is having the desired effect in the CNS,” said CJ Barnum, Ph.D., Head of Neurosciences at INmune Bio. “To see an impact on AD relevant disease pathways by three months that are sustained in patients that opted to enroll in the extension study for an additional nine months is more that we could have hoped for at this stage of development and will be of enormous value in planning the Phase 2 study.” RJ Tesi M.D., chief executive officer of INmune Bio, said, “With these data, we remain committed to initiating a Phase 2 clinical trial in patients with Alzheimer’s disease this year. Data from the Phase 1b trial will help determine the exact design of the Phase 2 trial which will be a blinded, randomized, placebo controlled clinical trial that will validate these biomarkers and begin to explore the clinical impact of XPro1595.” The Company will host a Key Opinion Leader webinar today, January 21, at 8:00am ET, where it will present biomarker data from six patients in the 1mg/kg treatment group in detail. The company will also report on the use novel MRI technologies to capture qualitative changes in both gray matter and white matter that may provide a more sensitive, non-invasive biomarker as compared to traditional volumetric MRI measures and CSF, respectively. These data are an extension and expansion of the data presented at the Company’s 13 July 2020 webinar. During that webinar, XPro1595 was shown to decrease neuroinflammation as measured by MRI analyzing white matter free water and other biomarkers. KOL Discussion Call Information To participate in the Webinar, please click the link below and register for the event: To register and access the live webinar click here Date: January 21, 2021 Time: 8:00 AM Eastern Time About XPro1595 XPro1595 is a next-generation inhibitor of tumor necrosis factor (TNF) that acts differently than currently existing TNF inhibitors in that it neutralizes soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro1595 could have substantial beneficial effects in patients with Alzheimer’s disease by decreasing neuroinflammation. For more information about the importance of targeting neuroinflammation in the brain to improve cognitive function and restore neuronal communication visit this section of the INmune Bio’s website. About INmune Bio, Inc. INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s and Treatment Resistant Depression (XPro1595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com. Information about Forward-Looking Statements Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, Quellor™, XPro1595, LIVNate™, and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. INmune Bio Contact: David Moss, CFO (858) 964-3720 DMoss@INmuneBio.com Investor Contact: Chuck Padala LifeSci Advisors (646) 627-8390 chuck@lifesciadvisors.com Media Contact: Meredith Sosulski, Ph.D. LifeSci Communications (929) 469-3851 msosulski@lifescicomms.com

INmune Bio, Inc. to Host Key Opinion Leader Webinar on Thursday, January 21 at 8 AM ET
01/13/2021 1:00 PM

Webinar to review expanded biomarker data from the company’s Phase 1b clinical trial of XPro1595 targeting neuroinflammation in patients with Alzheimer’s diseaseLA JOLLA, Calif, Jan. 13, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that the company will host a Key Opinion Leader (KOL) webinar on Thursday, January 21, from 8:00 AM – 9:00 AM Eastern Time. The webinar will present new biomarker data from the company’s Phase 1b trial of its lead clinical candidate, XPro1595, in patients with Alzheimer’s disease (AD) and biomarkers of inflammation. The primary goal of this 12 week trial is to demonstrate that XPro1595 decreases neuroinflammation. The Company will present expanded biomarker results in patients treated with XPro1595 for at least 12 weeks.  “We previously reported that XPro1595 decreased neuroinflammation in AD patients as measured by white matter free water (WMFW), a novel biomarker of inflammation that can be measured non-invasively by MRI,” stated CJ Barnum PhD, Head of Neurosciences at INmune Bio. “Consistent with our approach to study a small number of patients intensively in early phase studies, this updated data set will report on additional measures that support our primary goal of reducing neuroinflammation and address some of the exploratory biomarkers that relate to neurodegenerative disease.”Webinar participants include: * RJ Tesi, M.D., co-founder and Chief Executive Officer of INmune Bio. * Dr. CJ Barnum, Ph.D., Head of Neuroscience at INmune Bio. * Dr. Judith Jaeger Ph.D., President and Principal Scientist of CognitionMetrics, LLC. Dr. Jaeger is a cognitive neuropsychologist and internationally recognized expert in assessing cognitive endpoints. * Dr. Malú Gámez Tansey, Ph.D., Director, Center for Translational Research in Neurodegenerative Disease, Medical College of the University of Florida. Dr. Malu Tansey is an internationally recognized expert in neuroinflammation and neurodegenerative disease, including AD. Of note, Malu is an inventor of XPro’s DN-TNF technology and has been studying the drug’s effects on neuroinflammation for over 20 years.RJ Tesi, M.D., co-founder and CEO of INmune Bio, stated: “We look forward to presenting updated data from this important trial with XPro1595.  Our goal is to give investors and clinical experts the information they need to understand the role of XPro1595 in treating neuroinflammation in patients with AD.” KOL Discussion Call InformationTo participate in this event, you must register in advance. Please click on the link below.  After registering, you will receive a confirmation email containing information about joining the webinar.To register and access the live webinar click hereDate: January 21, 2021 Time: 8:00 AM Eastern TimeAbout XPro1595XPro1595 is a next-generation inhibitor of tumor necrosis factor (TNF) that acts differently than currently existing TNF inhibitors in that it neutralizes soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro1595 could have substantial beneficial effects in patients with Alzheimer’s disease by decreasing neuroinflammation. For more information about the importance of targeting neuroinflammation in the brain to improve cognitive function and restore neuronal communication visit this section of the INmune Bio’s website.About INmune Bio, Inc.INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s and Treatment Resistant Depression (XPro1595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.Information about Forward-Looking StatementsClinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, Quellor™, XPro1595, LIVNate™, and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.INmune Bio Contact: David Moss, CFO (858) 964-3720 DMoss@INmuneBio.comInvestor Contact: Chuck Padala LifeSci Advisors (646) 627-8390 chuck@lifesciadvisors.comMedia Contact: Meredith Sosulski, Ph.D. LifeSci Communications (929) 469-3851 msosulski@lifescicomms.com

Do Hedge Funds Love Inmune Bio Inc. (INMB)?
11/27/2020 3:59 PM

Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that’s why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]

Bexion Pharmaceuticals Announces the Addition of Dr. Raymond J. Tesi to Board of Directors
11/17/2020 3:33 PM

Bexion Pharmaceuticals, Inc. announced today that it has added RJ. Tesi, M.D. to its Board of Directors.

INmune Bio, Inc. Announces First Patient Dosed in Phase 2 Trial of Quellor™ for Pulmonary Complications in COVID-19 Patients
11/09/2020 12:00 PM

LA JOLLA, Calif, Nov. 09, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that the first patient has been dosed in its Phase 2 clinical trial evaluating Quellor™ for the treatment of pulmonary complications from COVID-19. Quellor™ is a selective soluble Tumor Necrosis Factor (sTNF) inhibitor designed to potentially prevent the progression of immune mediated pulmonary complications resulting from SARS-CoV-2 viral infection.“Clinical evidence over the last several months has shown that while infection with COVID-19 virus makes people sick, it’s the uncontrollable immune response and subsequent cytokine storm that is responsible for their admission to a hospital,” stated RJ Tesi, M.D., Chief Executive Officer of INmune Bio. “By neutralizing TNF, the master inflammatory cytokine of the cytokine storm with Quellor, we believe Quellor™ can blunt the symptoms of this dysregulated immune response.  This US based clinical trial expands both our geographic and therapeutic footprint with our DN-TNF platform.”The dosing of the first patient took place at UofL Health – Jewish Hospital, Louisville, KY. As the largest academic health system in Kentucky, UofL Health is committed to increasing regional access to leading edge treatments and therapies.The double-blind, randomized, placebo-controlled Phase 2 clinical trial (NCT04370236) will enroll 366 COVID-19 high risk patients in two equal sized cohorts: standard of care (SOC), which may include remdesivir, and SOC plus Quellor™ given as a 1mg/kg subcutaneous injection on admission to the hospital. A second dose of Quellor™ may be given a week later if the patient remains hospitalized. High risk patients include the elderly, patients with diabetes, cardiovascular disease, obesity, African American or Hispanic ethnicity.  The primary study endpoint is the need for mechanical ventilation during the 28 days following admission to the hospital, including CPAP, BiPAP or intubation. Secondary endpoints include transfer to the ICU, new onset neurologic, cardiovascular or thromboembolic disease, development of renal failure or death. The first 100 patients randomized into the study will provide proof-of-concept and inform a “go/no go” decision by the Data Safety Monitoring Board (DSMB). If the DSMB recommends that the trial continue, the remaining 266 patients will be enrolled.About Quellor™Quellor™ is a next-generation inhibitor of tumor necrosis factor (TNF) that is different from currently existing non-selective TNF inhibitors. Quellor™ neutralizes soluble TNF (sTNF) using a novel dominant-negative biology that importantly does not affect trans-membrane TNF (tmTNF) or TNF receptors. Currently approved TNF inhibitors block both sTNF and tmTNF. Quellor™ could have beneficial effects in patients with immune mediated complications from COVID-19 by decreasing inflammation and inflammatory immune complications such as endothelial cell activation, a potentially important cause of COVID-19-related coagulopathy which is increasingly blamed for end-organ dysfunction in lungs, kidneys, heart and brain. By targeting only sTNF, Quellor™ does not cause immunosuppression that is typical of most anti-cytokine therapies including currently approved anti-TNF and anti-IL-6 therapies. This may be an advantage when treating patients with a life-threatening viral infection.About UofL HealthUofL Health is a fully integrated regional academic health system with five hospitals, four medical centers, nearly 200 physician practice locations, more than 700 providers, the Frazier Rehab Institute and James Graham Brown Cancer Center. With more than 12,000 team members – physicians, surgeons, nurses, pharmacists and other highly skilled health care professionals, UofL Health is focused on one mission—one purpose—delivering patient-centered care to each and every patient—each and every day.About UofL Health – Jewish Hospital Jewish Hospital, part of UofL Health, is an internationally renowned, high-tech tertiary referral center, developing leading-edge advancements in hand and microsurgery, heart and lung care, orthopedics and sports medicine, neuroscience, organ transplantation and outpatient care. The hospital is the site of the world’s first successful hand transplant and AbioCor® implantable replacement heart procedures, in addition to the first trial of adult cardiac stem cells in chronic heart failure. Jewish Hospital continues to be recognized for its specialized heart care procedures, including the implantation of ventricular assist devices (VAD), and transcatheter aortic valve replacement (TAVR). The UofL Health – Trager Transplant Center is in a select group of hospitals nationwide that perform heart, lung, liver, kidney, pancreas and hand transplantation. The center also includes a Pancreas Disease Center, a GI Motility Clinic, and Advanced Heart Failure and Ventricular Assist Device programs.About INmune Bio, Inc.INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s (XPro1595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.Information about Forward-Looking StatementsClinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, Quellor™, XPro1595, LIVNate™, and INKmune™ are still in clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.INmune Bio Contact: David Moss, CFO (858) 964-3720 DMoss@INmuneBio.com Investor Contact: Chuck Padala LifeSci Advisors (646) 627-8390 chuck@lifesciadvisors.comMedia Contact: Meredith Sosulski, Ph.D. LifeSci Communications (929) 469-3851 msosulski@lifescicomms.com

INmune Bio, Inc. Announces Third Quarter Results and Provides Business Update
11/05/2020 9:00 PM

Company to host conference call today, November 5, at 4:30pm ETLA JOLLA, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today reported its financial results for the third quarter ended September 30, 2020 and provided a business update. “Since our second quarter update, we have made progress with our neuroinflammation franchise. First, we reported positive Phase 1b data in July demonstrating that XPro1595 decreased neuroinflammation by more than 40% in the arcuate fasciculus, a white matter pathway important for learning and memory in Alzheimer’s patients. More recently, we announced receipt of an NIH Small Business Innovation Research Grant of up to $2.9 million to support a Phase 2 study of XPro1595 in treatment resistant depression patients, or TRD,” stated RJ Tesi, M.D., Chief Executive Officer of INmune Bio. “We believe that TRD represents an important expansion of our neuroinflammation program, and we are working hard to initiate Phase 2 trials in Alzheimer’s and TRD next year.”“In addition, we continue to advance our other programs across both our DN-TNF and INKmune platforms. In DN-TNF, we have opened a Phase II clinical trial using Quellor to treat patients hospitalized from complications of COVID-19. In 2021, assuming the clinical landscape has not changed, and the pandemic is controlled, we will initiate planning for the Phase II trials of LIVNate in NASH and INB03 in cancer. We are also poised to advance our INKmune programs in ovarian cancer and high-risk MDS as well. Overall, we are pleased with our progress in the third quarter and year-to-date,” concluded Dr. Tesi.Q3 2020 and Recent Corporate HighlightsDN-TNF Platform Highlights: * Announced interim Phase Ib data demonstrating that over a 12-week period, XPro1595 decreased neuroinflammation by 40.6% in the arcuate fasciculus, a white matter pathway important for learning and memory in patients with Alzheimer’s disease. The 13 July KOL webinar discussing the data can be found by clicking here. * Awarded a National Institutes of Health (NIH) Small Business Innovation Research Grant of up to $2.9 million to support a phase 2 study of XPro1595 in patients with treatment resistant depression (TRD). The study, entitled, “Effects of the Next Generation TNF Inhibitor (XPro1595) on Inflammation-related Deficits in Reward Circuitry and Motivation in Depression,” will be conducted at two sites in the U.S. – Emory University School of Medicine in Atlanta and University of Alabama in Birmingham. * Hosted a Key Opinion Leader (KOL) webinar on the topic of treatment resistant depression. The webinar discussed the role of neuroinflammation in TRD and featured presentations by two highly-regarded thought leaders in the field: Charles Raison, M.D., professor in the department of psychiatry at the University of Wisconsin at Madison, and John E. Schneider, Ph.D., chief executive officer and principal of Avalon Health Economics. A replay of the webinar can be found by clicking here. * Announced FDA acceptance of an Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating Quellor™, a selective soluble tumor necrosis factor (sTNF) inhibitor, for the treatment of immune mediated complications in COVID-19 patients. * Announced that the European Patent Office has granted a patent covering XPro1595 and its peripheral administration for treating Alzheimer’s disease and other diseases of the CNS. The patent expires in 2033. NK Priming Platform Highlights: * Announced that the US Patent and Trademark Office has issued a patent covering a method for treating cancer using INKmune™, the company’s natural killer (NK) cell priming technology. The patent expires in 2036. Financial Highlights: * Closed a $25 million public offering of common stock, including full exercise of the underwriters’ over-allotment option, resulting in net proceeds of approximately $23.1 million. Upcoming Milestones:2020: * Enroll first patient in Phase II Quellor™ program, targeting COVID-19 patients with immune mediated complications from COVID-19. 2021: * Report additional data on Phase 1b XPro1595 in Alzheimer’s Disease in January 2021. The company will host a KOL call in tandem with the announcement. * XPro1595 Phase 2 program for treatment resistant depression. * XPro1595 Phase 2 program for Alzheimer's disease in patients with neuro-inflammation. The company plans additional clinical trials after the COVID-19 pandemic has been controlled. The exact timing of these trials cannot be predicted at this time: * INKmune Phase 1 program for ovarian cancer. * INKmune Phase 1 program for high-risk MDS. * LIVNate Phase 2 program for NASH. * INB03 Phase 2 program for MUC4 expressing cancer.Financial Results for the Third Quarter Ended September 30, 2020:Net loss attributable to common stockholders for the third quarter ended September 30, 2020 was approximately $4.7 million, compared to approximately $3.1 million for the quarter ended September 30, 2019.Research and development expense totaled approximately $2.4 million for the third quarter ended September 30, 2020, compared to approximately $1.2 million during the third quarter ended September 30, 2019.General and administrative expense was approximately $2.5 million for the quarter ended September 30, 2020, compared to approximately $1.9 million during the third quarter ended September 30, 2019.As of September 30, 2020, the Company had cash and cash equivalents of approximately $24.3 million and no debt. September 30 cash and cash equivalents reflects a public offering of common stock which the company completed in July which raised net proceeds of approximately $23.1 million.As of November 5, 2020, the Company had approximately 13.4 million common shares outstanding.Earnings Call InformationTo participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.Date: Thursday, November 5, 2020 Time: 4:30 PM Eastern Time Participant Dial-in: 800-909-4145 Participant Dial-in (international): 415-226-5358A transcript will follow approximately 24 hours from the scheduled call. A replay will also be available through November 12 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering PIN no. 21970461.About XPro1595XPro1595 is a next-generation inhibitor of tumor necrosis factor (TNF) that is currently in clinical trial and acts differently than currently existing TNF inhibitors in that it neutralizes soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro1595 could have substantial beneficial effects in patients with neurologic disease by decreasing neuroinflammation. For more information about the importance of targeting neuroinflammation in the brain to improve cognitive function and restore neuronal communication visit this section of the INmune Bio’s website. About INmune Bio, Inc.INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is in clinical trial to determine if it can treat for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s and treatment resistant depression (XPro595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.Forward Looking StatementsClinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595, LIVNate, Quellor™ and INKmune are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. Our two platforms are beginning clinical trials and there cannot be any assurance of the success of these trials. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.INmune Bio Contact:  David Moss, CFO (858) 964-3720 DMoss@INmuneBio.comInvestor Contact: Chuck Padala LifeSci Advisors (646) 627-8390 chuck@lifesciadvisors.comMedia Contact: Meredith Sosulski, Ph.D. LifeSci Communications (929) 469-3851 msosulski@lifescicomms.com The following table summarizes our results of operations for the periods indicated:INMUNE BIO, INC. CONSOLIDATED BALANCE SHEETS (Unaudited)  September 30, 2020  December 31, 2019          ASSETS         CURRENT ASSETS         Cash and cash equivalents $24,311,153  $6,995,525  Research and development tax incentive receivable  1,465,377   568,139  Other tax receivable  143,657   77,225  Prepaid expenses  216,871   97,623  Prepaid expenses – related party  -   26,266            TOTAL CURRENT ASSETS  26,137,058   7,764,778            Operating lease – right of use asset – related party  165,388   191,543  Acquired in-process research and development intangible assets  16,514,000   16,514,000            TOTAL ASSETS $42,816,446  $24,470,321            LIABILITIES AND STOCKHOLDERS’ EQUITY                   CURRENT LIABILITIES         Accounts payable and accrued liabilities $1,191,086  $401,989  Accounts payable and accrued liabilities – related parties  9,132   290,102  Deferred liabilities  253,709   -  Operating lease, current liability – related party  20,183   8,288  TOTAL CURRENT LIABILITIES  1,474,110   700,379            Long-term operating lease liability – related party  136,043   160,164  TOTAL LIABILITIES  1,610,153   860,543            COMMITMENTS AND CONTINGENCIES                   STOCKHOLDERS’ EQUITY         Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding  -   -  Common stock, $0.001 par value, 200,000,000 shares authorized, 13,447,948 and 10,770,948 shares issued and outstanding, respectively  13,448   10,771  Additional paid-in capital  71,351,634   44,833,703  Common stock issuable  50,000   50,000  Accumulated other comprehensive loss  (37,735)  (8,515) Accumulated deficit  (30,171,054)  (21,276,181) TOTAL STOCKHOLDERS’ EQUITY  41,206,293   23,609,778            TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $42,816,446  $24,470,321  INMUNE BIO, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)  For the Three Months Ended September 30,  For the Nine Months Ended September 30,    2020  2019  2020  2019  REVENUE $-  $-  $-  $-                    OPERATING EXPENSES                 General and administrative  2,456,266   1,916,200   4,960,106   4,550,306  Research and development  2,362,880   1,167,986   4,058,710   2,415,390  Waiver of common stock issuable  -   -   -   (1,542,000) Total operating expenses  4,819,146   3,084,186   9,018,816   5,423,696                    LOSS FROM OPERATIONS  (4,819,146)  (3,084,186)  (9,018,816)  (5,423,696)                   OTHER INCOME  102,484   17,220   123,943   63,602                    NET LOSS $(4,716,662) $(3,066,966) $(8,894,873) $(5,360,094)                   Net loss per common share – basic and diluted $(0.36) $(0.28) $(0.77) $(0.53)                   Weighted average common shares outstanding - basic and diluted  12,926,539   10,762,473   11,496,753   10,105,675                    COMPREHENSIVE LOSS                 Net loss $(4,716,662) $(3,066,966) $(8,894,873) $(5,360,094) Other comprehensive loss on foreign currency translation  (47,861)  (35,542)  (29,220)  (61,278)                   Total comprehensive loss $(4,764,523) $(3,102,508) $(8,924,093) $(5,421,372) INMUNE BIO, INC.CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)  For the Nine Months Ended September 30,    2020  2019  CASH FLOWS FROM OPERATING ACTIVITIES:         Net loss $(8,894,873) $(5,360,094) Adjustments to reconcile net loss to net cash used in operating activities:         Stock-based compensation  2,409,066   2,924,091  Waiver of common stock issuable  -   (1,542,000) Changes in operating assets and liabilities:         Research and development tax incentive receivable  (897,238)  (361,769) Other tax receivable  (66,432)  (68,460) Joint development cost receivable  -   17,989  Prepaid expenses  (119,248)  (106,478) Prepaid expenses – related party  26,266   (118,602) Accounts payable and accrued liabilities  789,097   (215,983) Accounts payable and accrued liabilities – related parties  (65,209)  (108,434) Deferred liabilities  253,709   -  Operating lease liability – related party  13,929   (11,546) Net cash used in operating activities  (6,550,933)  (4,951,286)           CASH FLOWS FROM FINANCING ACTIVITIES:         Net proceeds from sale of common stock  24,907,781   12,209,021  Purchase of common stock  (1,012,000)  -  Net cash provided by financing activities  23,895,781   12,209,021            Impact on cash from foreign currency translation  (29,220)  (61,278)           NET INCREASE IN CASH  17,315,628   7,196,457            CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD  6,995,525   186,204            CASH AND CASH EQUIVALENTS AT END OF PERIOD $24,311,153  $7,382,661            SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:         Cash paid for income taxes $-  $-  Cash paid for interest expense $-  $-            NONCASH INVESTING AND FINANCING ACTIVITIES:         Capital contribution $215,761  $-  Cashless exercise of warrants $2  $-  Issuance of warrants to placement agents $-  $247,452  Issuance of common stock issuable $-  $3,084,000

INmune Bio, Inc. to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on Thursday, November 5
10/29/2020 12:30 PM

Management to host conference call at 4:30 pm ET on that dayLA JOLLA, Calif, Oct. 29, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it will host a conference call on Thursday, November 5, 2020 at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2020 and to provide a corporate update.Conference Call InformationTo participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Third Quarter Conference Call when reaching an operator.Date: November 5, 2020 Time: 4:30 PM Eastern Time Participant Dial-in: 800-909-4145 Participant Dial-in (international): 415-226-5358A transcript will follow approximately 24 hours from the scheduled call. A replay will also be available through November 12 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering PIN no. 21970461.About INmune Bio, Inc.INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently in clinical trials to determine if it can help treat for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s and treatment resistant depression (XPro595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.Forward Looking Statements The Company’s clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595, LIVNate, Quellor™ and INKmune are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. Our two platforms are beginning clinical trials and there cannot be any assurance of the success of these trials. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.INmune Bio Contact: David Moss, CFO (858) 964-3720 DMoss@INmuneBio.comInvestor Contact: Chuck Padala LifeSci Advisors, LLC (917) 741-7792 Chuck@lifesciadvisors.com

Do Insiders Own Lots Of Shares In INmune Bio, Inc. (NASDAQ:INMB)?
10/26/2020 11:51 AM

A look at the shareholders of INmune Bio, Inc. (NASDAQ:INMB) can tell us which group is most powerful. Insiders often...

INmune Bio, Inc. Presents Preliminary Phase I Data at 21st International Conference on Alzheimer’s Drug Discovery
10/05/2020 1:00 PM

LA JOLLA, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced  that CJ Barnum PhD, Head of Neurosciences will present data from the ongoing biomarker directed Phase Ib study of neuroinflammation in patients with Alzheimer’s disease.  The talk entitled, Phase 1b Study in AD Patients with Neuroinflammation​, will be given today at 11:20AM ET as part of this year’s virtual 21st International Conference on Alzheimer’s Drug Discovery meeting.  The trial continues to enroll patients and additional data on the Phase Ib study will be presented in the near future. “Neuroinflammation plays an important role in the pathophysiology of Alzheimer’s disease,” said CJ Barnum PhD, Head of Neurosciences at INmune Bio.  “The preliminary data, albeit in a small number of patients, demonstrate that XPro1595, when given via subcutaneous injection, decreases neuroinflammation in the arcuate fasciculus, a white matter tract critical for the proper use of language.”  White Matter Free Water (WMFW) is a novel biomarker of inflammation measured using non-invasive neuroimaging by functional MRI.  Increases in WMFW biomarkers occur in Alzheimer’s patients as the disease progresses.  Preliminary data in the first 6 patients showed that treatment with XPro1595 decreased WMFW on average by 40% in the arcuate fasciculus (range 20-50%).  XPro1595 is a selective inhibitor of soluble Tumor Necrosis Factor (sTNF), a key inflammatory cytokine implicated in causing neuroinflammation in patients with neurologic disease including treatment resistant depression, Alzheimer’s disease and potentially other neurodegenerative diseases.  This Phase Ib multi-center, open label study will enroll patients with biomarkers of inflammation that have Alzheimer’s disease.  Patients are treated for 12 weeks.  Multiple measures of neuroinflammation are studied including biomarkers of inflammation in blood, CSF, and breath as well as neuroimaging biomarkers studied by MRI and behavioral end-points commonly seen in AD patients such as depression, aggression, apathy, anhedonia and sleep disorders. Measures of cognitive decline are measured as part of the trial, but due to the small size, short duration and variable disease status at time of enrollment, changes in cognitive function are not primary endpoints. “The use of novel biomarkers is a hallmark of INmune Bio’s clinical development programs,” said RJ Tesi MD, CEO of INmune Bio. “The use of biomarkers may allow smarter, smaller and faster clinical trials in patients with neurodegenerative diseases.” About XPro1595XPro1595 is a next-generation inhibitor of tumor necrosis factor (TNF) that acts differently than currently existing TNF inhibitors in that it neutralizes soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro1595 could have substantial beneficial effects in patients with Alzheimer’s disease by decreasing neuroinflammation. For more information about the importance of targeting neuroinflammation in the brain to improve cognitive function and restore neuronal communication visit this section of the INmune Bio’s website.  About INmune Bio, Inc.INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s and treatment resistant depression (XPro595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com. Forward Looking StatementsThe Company’s clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595, LIVNate, Quellor™ and INKmune are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. Our two platforms are beginning clinical trials and there cannot be any assurance of the success of these trials. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. INmune Bio Contact:  David Moss, CFO (858) 964-3720 DMoss@INmuneBio.comInvestor Contact: Chuck Padala LifeSci Advisors (646) 627-8390 chuck@lifesciadvisors.com  Media Contact: Meredith Sosulski, Ph.D. LifeSci Communications (929) 469-3851 msosulski@lifescicomms.com

INmune Bio, Inc. to Host Key Opinion Leader Webinar on Treatment Resistant Depression on Tuesday, September 29
09/23/2020 10:00 AM

LA JOLLA, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that the Company will be hosting a Key Opinion Leader (KOL) webinar on the topic of treatment resistant depression (TRD) at 1:00p.m. ET on Tuesday, September 29, 2020. The webinar will discuss the role of neuroinflammation in TRD and will feature presentations by two highly-regarded thought leaders in the field: Charles Raison, M.D., professor in the department of psychiatry at the University of Wisconsin at Madison, and John E. Schneider, Ph.D., chief executive officer and principal of Avalon Health Economics. INmune Bio has recently been awarded a $2.9 million Small Business Innovation Research (SBIR) grant (which will be disbursed to the Company in stages) from the National Institutes of Health (NIH) to support a Phase 2 study of its lead clinical candidate, XPro1595, in patients with TRD.   Management will provide an overview of the trial design.To register and access the live webinar click here or use this link: https://zoom.us/webinar/register/WN_jBsKRkSGSF2VThn6hh5V0ADate: September 29, 2020Time: 1:00 PM Eastern TimeCharles Raison, M.D., professor in the department of psychiatry at the University of Wisconsin at MadisonDr. Raison is the Mary Sue and Mike Shannon Chair for Healthy Minds, Children & Families in the School of Human Ecology and a Professor in the Department of Psychiatry at the University of Wisconsin – Madison. Dr. Raison received his medical degree from Washington University in St Louis, Missouri, where he was elected to Alpha Omega Alpha and won the Missouri State Medical Association Award. He completed residency training at the UCLA Neuropsychiatric Institute and Hospital in Los Angeles. In addition to his medical training, Dr. Raison obtained his Masters of English from the University of Denver.Dr. Raison has written and published more than 100 scientific papers as well 20 review papers and editorials. Chapters he has written have been featured in more than 30 books, and he has written two books, most recently “The New Mind-Body Science of Depression” published by WW Norton in 2017. Dr. Raison’s publications have been cited more than 14,000 times, with three publications having more than 1,000 citations. His H-index is 44. The recipient of several teaching awards, Dr. Raison has received research funding from the National Institute of Mental Health, National Center for Complementary and Alternative Medicine, and the Centers for Disease Control and Prevention. His visionary work focuses on the treatment of depression in response to illness and stress, translating neurobiological findings into novel interventions. In addition to his activities at University of Wisconsin-Madison, Dr. Raison is the mental health expert for CNN.com.John E. Schneider, Ph.D., chief executive officer and founder of Avalon Health EconomicsJohn E. Schneider is the CEO and founder of Avalon Health Economics. Dr. Schneider was one of the founding partners of the Health Economics Consulting Group, LLC (HECG), which formed in 2004. HECG merged with the UK-based Oxford Outcomes in 2009, and from 2009-2013 Dr. Schneider served as Senior Director of the U.S. health economics operations of Oxford Outcomes, which also included facilitating integration between Oxford Outcomes and ICON plc in 2011. He started Avalon Health Economics in 2013 by bringing together the consulting practices of several industry and academic colleagues, building on what he started with HECG in 2004. Prior to starting HECG, Dr. Schneider was on the faculty in the Department of Health Management and Policy and the Department of Economics at the University of Iowa. His Ph.D. is in health services and policy analysis from the University of California, Berkeley, with a concentration in health economics. He has more than 25 years of experience studying economic and organizational aspects of the health care industry, including professional appointments at the Center for Health Economics Research (Waltham, MA; now part of RTI International), and the California Association of Health Plans (Sacramento, CA). Dr. Schneider has also served as a consultant to managed care organizations, state health departments, trade associations, medical device manufacturers, large pharmaceutical companies, and others. Some of his research has been published in Medical Care Research and Review, International Journal of Healthcare Finance and Economics, Tobacco Control, Health Economics Review, Health Affairs, Inquiry, Health Services Research, Review of Industrial Organization, International Journal of Technology Assessment in Health Care, American Journal of Medical Science, Prevention Science, and Health Care Financing Review. He is co-author of The Business of Health (AEI Press, 2006).Disclaimer: Research reported in this publication was supported by the National Institute of Mental Health of the National Institutes of Health under Award Number R44MH125480. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.About XPro1595XPro1595 is a next-generation inhibitor of tumor necrosis factor (TNF) that acts differently than currently existing TNF inhibitors in that it neutralizes soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro1595 could have substantial beneficial effects in patients with neurologic disease by decreasing neuroinflammation. For more information about the importance of targeting neuroinflammation in the brain to improve cognitive function and restore neuronal communication visit this section of the INmune Bio’s website. About INmune Bio, Inc.INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s and treatment resistant depression (XPro1595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.Forward Looking StatementsClinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595, LIVNate, Quellor™ and INKmune are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. Our two platforms are beginning clinical trials and there cannot be any assurance of the success of these trials. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.INmune Bio Contact:  David Moss, CFO (858) 964-3720 DMoss@INmuneBio.comInvestor Contact: Chuck Padala LifeSci Advisors (646) 627-8390 chuck@lifesciadvisors.comMedia Contact: Meredith Sosulski, Ph.D. LifeSci Communications (929) 469-3851 msosulski@lifescicomms.com

INmune Bio, Inc. Awarded $2.9 Million NIH Small Business Innovation Research Grant to Support Phase 2 Study of XPro1595 in Patients with Treatment Resistant Depression
09/16/2020 11:00 AM

100 patient blinded, randomized, biomarker-directed Phase 2 study will use neuroimaging technology to study the complex biology of treatment resistant diseaseStudy supports INmune Bio’s approach to treating inflammation as a common mechanism in neurologic diseaseAccompanying Key Opinion Leader webinar to be hosted on September 29, 2020 to discuss the role of neuroinflammation in treatment resistant depressionLA JOLLA, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced it has received a $2.9 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH), of which (subject to the terms of the grant), the Company will receive $739,739 this year, $1,210,682 next year with the balance to be received in 2022. The grant will support a Phase 2 study of XPro1595 in patients with treatment resistant depression. The study, entitled, “Effects of the Next Generation TNF Inhibitor (XPro1595) on Inflammation-related Deficits in Reward Circuitry and Motivation in Depression,” will be conducted at two sites in the U.S. – Emory University School of Medicine in Atlanta and University of Alabama in Birmingham. “Treatment resistant depression is a major problem affecting more than seven million patients in the U.S. alone,” said CJ Barnum Ph.D., head of neurosciences at INmune Bio. “This grant is a collaboration with two highly-regarded thought leaders in this difficult to treat condition: Professor Andrew H. Miller, M.D. and Associate Professor Jennifer Felger, Ph.D., both at Emory University. Dr. Miller is the foremost expert in neuroinflammation and depression and published the first study demonstrating that anti-TNF treatment could improve depressive symptoms in patients that had high levels of the inflammatory marker C-Reactive Protein (CRP), a biomarker that will be used to select patients in our study. In addition, Dr. Felger discovered that the connection between two regions of the brain, vital for feelings of pleasure and motivation, are lost in depressed patients with inflammation. Our hypothesis is that XPro1595 will restore this connectivity.”XPro1595 is a selective inhibitor of soluble Tumor Necrosis Factor (sTNF), a key inflammatory cytokine implicated in causing neuroinflammation in patients with neurologic disease including treatment resistant depression, Alzheimer’s disease, and other neurodegenerative diseases. This Phase 2 multi-center, blinded, randomized study will enroll patients with treatment resistant depression that have biomarkers of inflammation and anhedonia (inability to feel pleasure). Neuroimaging biomarkers will be used to measure response to XPro1595. Patients will be studied with functional MRI to determine if functional connectivity in reward-related brain circuitry can be improved by reversing neuroinflammation, and if this translates into improvements in the clinical symptoms of anhedonia and motivation.  RJ Tesi M.D., chief executive officer of INmune Bio, added, “This award reinforces one of INmune Bio’s fundamental drug development tenets – by targeting the underlying biology, you can target a diverse group of diseases caused by inflammation. Through this Phase 2 study, we will evaluate the potential utility of XPro1595 to treat the biology of neuroinflammation which, we believe, will have a beneficial effect on patients suffering from treatment resistant depression. We recently presented preliminary data demonstrating that XPro1595 decreased neuroinflammation in Alzheimer’s disease, and we believe these findings provide strong rationale for study in this high-need neuroinflammatory indication as well.”The company will also host a Key Opinion Leader (KOL) webinar at 1 p.m. ET on Tuesday, September 29, 2020 to provide additional information about the role of neuroinflammation in treatment resistant depression. This webinar will feature presentations by Charles Raison, M.D., professor in the Department of Psychiatry at the University of Wisconsin at Madison, and John E. Schneider, Ph.D., chief executive officer and principal of Avalon Health Economics. Further details will be provided in the near future.Disclaimer: Research reported in this publication was supported by the National Institute of Mental Health of the National Institutes of Health under Award Number R44MH125480. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.About Treatment Resistant Depression Major Depressive Disorder (MDD) is highly prevalent, difficult to treat, and is one of the most disabling of all medical conditions worldwide. According to the National Institutes of Health, an estimated 20 million adults, experience MDD each year. At least one third (approximately seven million patients) are considered to have Treatment Resistant Depression (TRD), which is defined as persistence of depressive symptoms after the patient has failed to respond to two previous lines of conventional anti-depressant treatment of adequate dose and duration. Patients with TRD incur the highest direct and indirect medical costs among those with MDD. These costs increase with the severity of TRD. Treatment-resistant patients are twice as likely to be hospitalized, and their cost of hospitalization is more than six times the mean total cost for depressed patients who are not treatment resistant. account for nearly $64 billion of total costs.1,2About XPro1595XPro1595 is a next-generation inhibitor of tumor necrosis factor (TNF) that acts differently than currently existing TNF inhibitors in that it neutralizes soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro1595 could have substantial beneficial effects in patients with neurologic disease by decreasing neuroinflammation. For more information about the importance of targeting neuroinflammation in the brain to improve cognitive function and restore neuronal communication visit this section of the INmune Bio’s website. About INmune Bio, Inc.INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s and treatment resistant depression (XPro595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.Forward Looking StatementsClinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595, LIVNate, Quellor™ and INKmune are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. Our two platforms are beginning clinical trials and there cannot be any assurance of the success of these trials. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.1 Mrazek, et al. A Review of the Clinical, Economic, and Societal Burden of Treatment- Resistant Depression: 1996–2013. Psychiatr Serv. 2014;65(8):977-987.2 Ionescu, et al. Pharmacological approaches to the challenge of treatment-resistant depression. Dialogues Clin Neurosci. 2015;17(2):111-126.INmune Bio Contact:  David Moss, CFO (858) 964-3720 dmoss@INmuneBio.comInvestor Contact: Chuck Padala LifeSci Advisors (646) 627-8390 chuck@lifesciadvisors.comMedia Contact: Meredith Sosulski, Ph.D. LifeSci Communications (929) 469-3851 msosulski@lifescicomms.com* * *